Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study
Authors
Keywords
-
Journal
American Journal of Cardiovascular Drugs
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-03-06
DOI
10.1007/s40256-019-00341-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding
- (2018) Alexa R. Hospodar et al. American Journal of Cardiovascular Drugs
- Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion
- (2017) Saga Itäinen et al. EUROPACE
- Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study
- (2017) A John Camm et al. EUROPACE
- NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world
- (2017) Emanuele Bertaglia et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- The clinical performance of dabigatran in the Italian real-life experience
- (2017) Vincenzo Russo et al. Journal of Cardiovascular Medicine
- Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study
- (2017) Vincenzo Russo et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
- (2016) Kostas Athanasakis et al. American Journal of Cardiovascular Drugs
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
- (2016) Paulus Kirchhof et al. EUROPEAN HEART JOURNAL
- A new integrated strategy for direct current cardioversion in non-valvular atrial fibrillation patients using short term rivaroxaban administration: The MonaldiVert real life experience
- (2016) Vincenzo Russo et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
- (2015) Walid Saliba American Journal of Cardiovascular Drugs
- Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: A multi center registry
- (2015) Giuseppe Stabile et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Comparison of the Phase III Clinical Trial Designs of Novel Oral Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial Fibrillation: Implications for Clinical Practice
- (2014) Carlos J. Gonzalez-Quesada et al. American Journal of Cardiovascular Drugs
- Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation
- (2013) Greg Flaker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
- (2009) Timothy Watson et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started